A Phase 2 interventional study of HL301 and HL301(Placebo) in Acute Bronchitis, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-16.
Sponsored by Hanlim Pharm. Co., Ltd. · Phase 2, Interventional, and Treatment
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HL301 versus Placebo in acute bronchitis patients.
Endpoint: BSS, The improvement and improvement rate of the tester for the treatment response, The satisfaction of the subject, Total usage of Acetaminophen
156 studies on the registry are indexed under Bronchitis; 21 are open to participants now.
This study's enrollment of 168 is close to the median of 185 across 105 interventional studies indexed under Bronchitis.
Browse Bronchitis studies →Hanlim Pharm. Co., Ltd. is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
Drug: HL301
HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
Drug: HL301(Placebo)
HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
Bronchitis Severity Total Score(BSS) Change
Evaluation period: Visit 1 (-3 day), Visit 2 (0 day), Visit 3 (7 day)
Time frame: Visit 1 (-3 day), Visit 2 (0 day), Visit 3 (7 day)
The improvement and improvement rate of the tester for the treatment response (Chi-square test or Fisher's Exact test)
Evaluation period: Visit 3 (7 day)
Time frame: Visit 3 (7 day)
The satisfaction of the subject (Questionnaire)
Evaluation period: Visit 3 (7 day)
Time frame: Visit 3 (7 day)
Total usage of Acetaminophen
Evaluation period: Visit 3 (7 day)
Time frame: Visit 3 (7 day)
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: R. glutinosa/P. suffruticosa/S. chinensis/A. cochinchinensis/P. armeniaca/S. baicalensis/S. sessilifolia Herbal Supplement HL301